



BIOCARTIS

BIOCARTIS AIMS TO BECOME A GLOBAL LEADING PLAYER IN MOLECULAR DIAGNOSTICS

BY PROVIDING INNOVATIVE, PERSONALIZED HEALTHCARE SOLUTIONS, ENABLING FAST AND EFFECTIVE DIAGNOSIS, TREATMENT SELECTION AND TREATMENT MONITORING



EARLY DIAGNOSIS

Biocartis brings...

More rapid diagnosis of disease

More sensitive identification of mutations

Comprehensive panels of pathogens in infectious disease



THERAPY SELECTION

Biocartis brings...

Identification of the right treatment for the right patient

Companion diagnostics to test alongside new drugs



PATIENT MONITORING

Biocartis brings...

Monitoring of treatment progress

Early detection of relapse

BIOCARTIS FAST FACTS



FOUNDED by Dr. Rudi Pauwels in 2007



HEADQUARTERED in Mechelen, Belgium



Around 200 EMPLOYEES (end December 2014)



Approx. €220* million PRIVATE FUNDING raised to date



SHAREHOLDERS include a.o. J&J, Debio Innovation, PMV, Philips and Hitachi Chemical

*Incl. investments in Evaluation™ platform spun out to MyCartis and excl. 3rd tranche of F-round

COMMERCIAL STAGE IDYLLA™ INSTANTLY DEPLOYABLE IN VIRTUALLY ANY SETTING

Idylla™ is a fully-automated molecular diagnostics system that offers clinicians fast and easy access to molecular diagnostics information. Idylla™ can be used on-demand from virtually any human clinical sample type and covers the entire process from sample to result in a time frame of 35 to 150 minutes.



SCAN SAMPLE WITH HUMAN MATERIAL



SCAN CARTRIDGE



LOAD SAMPLE INTO THE CARTRIDGE



INSERT CARTRIDGE INTO THE INSTRUMENT TRAY



ANALYSIS OF THE SAMPLE



RESULT IN 35 TO 150 MINUTES

PERSONALIZED MEDICINE WITHIN REACH THROUGH HIGH PRECISION DIAGNOSTICS

Every person has a unique genetic profile. Understanding this molecular mechanism empowers doctors to shift away from the one-drug-fits-all paradigm and tailor a treatment to the genetic profile of their patient, also known as 'personalized medicine'.

Specific molecular diagnostics tests can, for instance, help a doctor determine the preferred therapy for a patient with a specific genetic mutation. Eventually, this makes treatments more effective, improving outcomes and ultimately reducing healthcare costs.

However, in order to be truly sustainable and beneficial, molecular information needs to be gathered quickly and easily, at the point of need.

Today, this is not the case. Most hospitals do not perform molecular tests in-house, but send them to specialized labs where they are processed in batches, on multiple instruments and operated by highly trained personnel. This time-consuming and labor-intensive process delays treatment decisions which are often crucial to save patients' lives. Biocartis aims to make personalized medicine a daily practice.



STATE OF THE ART MANUFACTURING FACILITIES



Fully integrated company with full ability to conduct in-house commercial scale manufacturing of the Idylla™ platform

Approximately 100,000 cartridges, 400 instruments and 150 consoles manufactured to date



ESTABLISHING GLOBAL COMMERCIAL FOOTPRINT

Today Biocartis has a direct sales representation in 13 European countries and is building a strong and dedicated distributor network worldwide

Depending on regulatory approval, Biocartis expects to enter the U.S. market by 2016 and China by 2017

Initial customer focus in Europe will be on the large to mid-sized anatomical pathology laboratories

Biocartis has sold 98 instruments and has secured commitments from distributors to buy at least 127 instruments since it launched the Idylla™ platform in September 2014



COMPANY HIGHLIGHTS

Successful launch of the Idylla™ platform in September 2014 fully suited for high precision medicine

First oncology assay launched, the Idylla™ BRAF Mutation Test initially for melanoma

Rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases

Partnerships with key industry players Johnson & Johnson and Abbott Molecular to broaden assay menu

Operations and strategy in place to support commercial expansion


Strong endorsement of key opinion leaders and early adopters

Fully integrated business with strong and experienced management team



RAPIDLY EXPANDING TEST MENU

Focus on addressing key unmet clinical needs in **oncology and infectious diseases**, respectively the fastest growing and the largest segments of the estimated \$5.0 billion MDx market



Intention to launch at least 4 to 5 new assays per year, complemented by additional assays developed in conjunction with strategic partners (Johnson & Johnson, Abbott Molecular)

First commercial assay, the **Idylla™ BRAF Mutation Test**, detects a BRAF mutation in metastatic melanoma patients enabling targeted patient treatment

Oncology tests in development include solid tumor assays (a.o. KRAS, NRAS and MSI mutations in initially colon cancers) and liquid biopsy assays that enable early diagnosis and monitoring

The **infectious disease test menu in development** includes sepsis, respiratory viruses (flu) and HIV, HBV and HCV viral load assays

Biocartis is currently performing testing of a **Rapid Ebola Virus Triage Test** in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp in West-Africa